Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate.
The patent provides protection and market exclusivity of products based in the cell reprogramming method until 2038, such as Asgard’s innovative cancer immunotherapies, describes the company.
“We are very pleased with the grant of our first patent. It’s a great milestone on Asgard’s pathway to solidify our IP protection,” says Cristiana Pires, CEO and co-founder of Asgard Therapeutics. “We have an active IP strategy and work continuously to ensure a comprehensive protection in major markets world-wide as well as pipeline programs based on cell reprogramming.”
This patent covers combinations of transcription factors that are able to induce cell fate conversion of unrelated cells towards type 1 conventional dendritic cells. The reprogramming method is the basis of Asgard’s lead program, TrojanDC. TrojanDC is an in vivo gene therapy product that delivers reprogramming factors to convert cancer cells into immunogenic dendritic cells, allowing the presentation of their own antigens and inducing potent anti-cancer immune responses.
Corresponding applications are pending in several relevant territories, including the European Patent Office (EPO), China, Japan, and India. In addition, Asgard has other pending patent applications, which protect other aspects of the company’s technology.